However, this resistance can be overcome through TBC1D31 inhibition (by knockdown), or EGFR inhibition (by gefitinib), or their combined inhibition, which reduces the dependence of TBC1D31‐amplified HCC cells on the EGFR‐driven MAPK/ERK1/2 and PI3K/AKT pathways. This evidence concerns the gene EGFR and hepatocellular carcinoma.